Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling WorkTAMPA, Fla. and LONDON, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced the initiation of GMP manufacturing activities to support the development of AKTX-101, the Company’s lead ADC program. Akari has selected WuXi XDC, the world’s leading ADC contract development and manufacturin ...

Core Insights - Akari Therapeutics has appointed Kameel D. Farag as Interim Chief Financial Officer, bringing over 20 years of experience in biopharma and global finance [1][2][4] - The company is focused on developing novel antibody drug conjugates (ADCs) that utilize a unique spliceosome modulator payload, aiming to disrupt cancer cell survival [2][7] Company Overview - Akari Therapeutics is an oncology biotechnology company specializing in next-generation spliceosome payload ADCs, with a platform capable of generating and optimizing ADC candidates for various targets [7] - The lead asset, AKTX-101, has shown significant preclinical activity and prolonged survival compared to traditional ADCs, with potential synergy with checkpoint inhibitors [7] Leadership Background - Kameel D. Farag previously served as CFO at Aspen Neuroscience, where he tripled the company's headcount and secured over $150 million in financing [4] - Farag has also held senior finance roles at Ionis Pharmaceuticals and Amgen, contributing to substantial revenue growth and operational improvements [4]